Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H12O5 |
Molecular Weight | 272.2528 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(C(=O)\C=C\C2=CC=C(O)C(O)=C2)C(O)=C1
InChI
InChIKey=AYMYWHCQALZEGT-ORCRQEGFSA-N
InChI=1S/C15H12O5/c16-10-3-4-11(14(19)8-10)12(17)5-1-9-2-6-13(18)15(20)7-9/h1-8,16,18-20H/b5-1+
Molecular Formula | C15H12O5 |
Molecular Weight | 272.2528 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Butein, a plant polyphenol, has been reported to exhibit several important pharmacological effects, such as anti-inflammatory, anti-cancer, anti-oxidant and anti-angiogenic. It was first found in Toxicodendronvernicifluum, a tree widely used as a local food additive and therapeutic supplement in South East Asia. It can also be isolated from the heartwood of Dalbergiaodorifera, the seed of Cyclopiasubternata and the stems of Semecarpusanacardium, as well as many other plants. Butein was shown to be a specific protein tyrosine kinase inhibitor. This compound inhibited tyrosine-specific protein kinase activities of EGF receptor and p60(c-Src). In preclinical settings, it was shown to improve the treatment outcome of several chronic diseases including inflammation, neurological disorders, neoplasms, atherosclerosis, as well as infectious diseases, and most of these actions were accomplished by the inhibition of the transcription factor NF-κB and its downstream targets.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9571170 |
65.0 µM [IC50] | ||
Target ID: CHEMBL2363049 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9571170 |
16.0 µM [IC50] | ||
Target ID: Glutathione S-transferase (rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8010991 |
9.0 µM [IC50] | ||
Target ID: GO:0034440 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9630680 |
3.3 µM [IC50] | ||
Target ID: map04064 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28586006 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26694191
Mice: 1, 3 or 10 mg/kg was administered every day from 3 days before tumor cell injection to 21 days after tumor cell injection.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9571170
Butein up to 500 uM scarcely inhibited protein kinase C and cAMP-dependent protein kinase activities in HepG2 cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:53:21 GMT 2025
by
admin
on
Mon Mar 31 18:53:21 GMT 2025
|
Record UNII |
4WVS5M0LGF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1967
Created by
admin on Mon Mar 31 18:53:21 GMT 2025 , Edited by admin on Mon Mar 31 18:53:21 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4WVS5M0LGF
Created by
admin on Mon Mar 31 18:53:21 GMT 2025 , Edited by admin on Mon Mar 31 18:53:21 GMT 2025
|
PRIMARY | |||
|
5281222
Created by
admin on Mon Mar 31 18:53:21 GMT 2025 , Edited by admin on Mon Mar 31 18:53:21 GMT 2025
|
PRIMARY | |||
|
DTXSID101025569
Created by
admin on Mon Mar 31 18:53:21 GMT 2025 , Edited by admin on Mon Mar 31 18:53:21 GMT 2025
|
PRIMARY | |||
|
21849-70-7
Created by
admin on Mon Mar 31 18:53:21 GMT 2025 , Edited by admin on Mon Mar 31 18:53:21 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
487-52-5
Created by
admin on Mon Mar 31 18:53:21 GMT 2025 , Edited by admin on Mon Mar 31 18:53:21 GMT 2025
|
PRIMARY | |||
|
C1028
Created by
admin on Mon Mar 31 18:53:21 GMT 2025 , Edited by admin on Mon Mar 31 18:53:21 GMT 2025
|
PRIMARY | |||
|
BUTEIN
Created by
admin on Mon Mar 31 18:53:21 GMT 2025 , Edited by admin on Mon Mar 31 18:53:21 GMT 2025
|
PRIMARY | |||
|
3237
Created by
admin on Mon Mar 31 18:53:21 GMT 2025 , Edited by admin on Mon Mar 31 18:53:21 GMT 2025
|
PRIMARY | |||
|
207-659-5
Created by
admin on Mon Mar 31 18:53:21 GMT 2025 , Edited by admin on Mon Mar 31 18:53:21 GMT 2025
|
PRIMARY | |||
|
652892
Created by
admin on Mon Mar 31 18:53:21 GMT 2025 , Edited by admin on Mon Mar 31 18:53:21 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
IN VITRO
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |